PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2020.6812020353571-577A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial ProtocolEun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Parkhttp://e-enm.org/upload/pdf/enm-2020-681.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2020.681, http://e-enm.org/upload/pdf/enm-2020-681.pdf
Management of Differentiated Thyroid Cancer10.1007/978-3-319-54493-9_172017205-222Role of Radioactive Iodine for Remnant Ablation in Patients with Papillary Thyroid CancerNicole M. Iniguez-Ariza, Suneetha Kaggal, Ian D. Hayhttp://link.springer.com/content/pdf/10.1007/978-3-319-54493-9_17
Thyroid10.1089/thy.2012.0183201222101007-1015Recombinant Human Thyroid Stimulating Hormone–Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of RecurrenceJonathan Hugo, Eyal Robenshtok, Ravinder Grewal, Steve Larson, R. Michael Tuttlehttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2012.0183, https://www.liebertpub.com/doi/pdf/10.1089/thy.2012.0183
Head & Neck10.1002/hed.245502016391109-115Prediction of radioactive iodine remnant ablation failure in patients with differentiated thyroid cancer: A cohort study of 740 patientsMarin Prpic, Davor Kust, Ivan Kruljac, Lora Stanka Kirigin, Tomislav Jukic, Nina Dabelic, Ante Bolanca, Zvonko Kusichttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhed.24550, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhed.24550, http://onlinelibrary.wiley.com/wol1/doi/10.1002/hed.24550/fullpdf
Thyroid10.1089/thy.2011.04532012227760-761Stimulated Thyroglobulin and Neck Ultrasonography Facilitates Postsurgical Radioactive Iodine Remnant Ablation Selection in Patients with Low-Risk Well-Differentiated Thyroid CarcinomaKaren Gomez Hernandez, Daniel Etarsky, Steven Orlov, Paul G. Walfishhttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2011.0453, https://www.liebertpub.com/doi/pdf/10.1089/thy.2011.0453
European Thyroid Journal10.1159/0004428802016517-8Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid CancerFurio Pacinihttps://www.karger.com/Article/Pdf/442880, https://www.karger.com/Article/Pdf/442880
Thyroid Cancer10.1007/978-1-4939-3314-3_332016395-409Remnant Ablation, Adjuvant Treatment and Treatment of Locoregional Metastases with 131IDouglas Van Nostrandhttp://link.springer.com/content/pdf/10.1007/978-1-4939-3314-3_33
Thyroid10.1089/thy.2017.0303201727121582-1582Re: “Dynamic Risk Stratification for Predicting Recurrence in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy” by Park et al.: (Thyroid 2017;27:524–530)Erfan Ayubi, Mark J.M. Sullman, Saeid Safirihttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2017.0303, https://www.liebertpub.com/doi/pdf/10.1089/thy.2017.0303
Clinical Endocrinology10.1046/j.1365-2265.2000.01014.x2000526765-773Ablation of the thyroid remnant and 131 I dose in differentiated thyroid cancerSuhail A.R. Doi, Nicholas J.Y. Woodhousehttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2265.2000.01014.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2265.2000.01014.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2265.2000.01014.x/fullpdf
Endocrine10.1007/s12020-015-0668-9201550161-66Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: prosKenneth B. Ainhttp://link.springer.com/content/pdf/10.1007/s12020-015-0668-9.pdf, http://link.springer.com/article/10.1007/s12020-015-0668-9/fulltext.html, http://link.springer.com/content/pdf/10.1007/s12020-015-0668-9